Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Download White Paper
IT in
Healthcare,
Patient
Monitoring &
Telemedicine

Download White Paper

 
Matching geography
Reports matching your search in:
 
 
Download SlideShare
20
Hot
Stats on
Healthcare
IT

Download SlideShare

 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology: market research reports

1594
Neurology and the CNS is the branch of science dealing with anatomy, function, diagnosis and treatment of disorders and disease affecting the central nervous system (brain and spinal cord). Neuroscience medicine includes but is not limited to the study and treatment of Alzheimer’s disease, major depressive disorder, schizophrenia, Parkinson’s disease, epilepsy/seizures, migraine, insomnia/sleep disorders, bipolar disorder, and ADHD.

A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.

Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.

RSS Feeds

CNS/Neurology market research reports and industry analysis

< prev 1  2  3  4  5  6  7  8  9  10  next >
Obsessive-Compulsive Disorder – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... for Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... This report provides information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ...  |  read more...
$2,000.00
Brain Ischemia – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... for Brain Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Ischemia. Brain Ischemia - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Malignant Glioma – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Malignant Glioma - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Tinnitus – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tinnitus. Tinnitus - Pipeline Review, Half Year is built using data and ...  |  read more...
$2,000.00
High-Grade Glioma – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... for High-Grade Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for High-Grade Glioma. High-Grade Glioma - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
... on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme ...  |  read more...
$2,000.00
Mental Illness Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ...  |  read more...
$2,000.00
Central Nervous System Disorder Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. ...  |  read more...
$2,000.00
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
4/30/2013 | published by: GBI Research
... to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the ...  |  read more...
$3,500.00
Disruptive Behavior Disorder – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... therapeutic development for Disruptive Behavior Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Disruptive Behavior Disorder. Disruptive Behavior Disorder ...  |  read more...
$2,000.00
Motor Neurone Diseases – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... therapeutic development for Motor Neurone Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Motor Neurone Diseases. Motor Neurone Diseases ...  |  read more...
$2,000.00
Tension -Type Headache Global Clinical Trials Review, H1, 2013
4/30/2013 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Tension -Type Headache. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
$2,500.00
Acute Spinal Cord Injury – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord ...  |  read more...
$2,000.00
Essential Tremor – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... for Essential Tremor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Essential Tremor. Essential Tremor - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Global Deep Brain Stimulator Market 2012-2016
4/26/2013 | published by: Infiniti Research Limited
... this market growth is the rapidly increasing awareness about deep brain stimulation devices in the US. The Global Deep Brain Stimulator market has also been witnessing the emergence of less invasive and non-invasive treatments. However, ...  |  read more...
$2,000.00
The Depression Market Forecast to 2021
4/25/2013 | published by: Datamonitor
... five major EU markets in 2012 Features and benefits Excel and pdf with forecasts through to 2021 covering the US, Japan, and 5 major EU markets, to allow you to assess future growth opportunities Analysis ...  |  read more...
$8,000.00
Anorexia Nervosa Global Clinical Trials Review, H1, 2013
4/22/2013 | published by: GlobalData
... and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  read more...
$2,500.00
Brain Cancer Drug Pipeline Update 2013
4/22/2013 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
$5,621.25
Psychiatric Disorders – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year ...  |  read more...
$2,500.00
Partial Seizure – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure. Partial Seizure - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Memory Impairment – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Memory Impairment. Memory Impairment - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder ...  |  read more...
$2,000.00
Dyslexia Global Clinical Trials Review, H1, 2013
4/12/2013 | published by: GlobalData
... relating to the clinical trials on Dyslexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
$2,500.00
Alcohol Addiction – Pipeline Review, H1 2013
4/10/2013 | published by: Global Markets Direct
... for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Alcohol Addiction - Pipeline Review, Half Year ...  |  read more...
$2,000.00
< prev 1  2  3  4  5  6  7  8  9  10  next >